Gesprächsführung. Moderne Krebstherapien ermöglichen Patienten mit
fortgeschrittenen Karzinomen eine längere Lebenserwartung. Dadurch
werden Ärzte in der Kommunikation mit den Betroffenen mit Situationen
konfrontiert, für die sie nicht entsprechend ausgebildet wurden.
From 4th to 7th December, 2016, the IASLC 17th World Conference on
Lung Cancer (WCLC) took place in Vienna, Austria, attracting more than
6,500 participants from 93 countries. Scientific insights presented at
the IASLC WCLC 2016 are summarised in this memo inOncology congress
report that covers a range of topics relating to the diagnosis and
treatment of lung
01/2017 | 15 Kommentare
Treatment with the ALK tyrosine kinase inhibitor (TKI) crizotinib has
been established as a standard first-line option in patients with
_ALK_-rearranged advanced NSCLC. Before the advent of crizotinib, a
platinum–pemetrexed doublet followed by pemetrexed maintenance was
standard of care in non-squamous NSCLC.
The irreversible ErbB family blocker afatinib and the reversible EGFR
TKIs gefitinib and erlotinib have been approved as first-line
therapies for treatment of NSCLC patients with _EGFR_-sensitising
mutations. However, resistance frequently develops, which indicates
the need for new agents.
Amplification or overexpression of _HER2_ (_ErbB2_) has been
identified in NSCLC, and somatic _HER2_ mutations occur in
approximately 2 % to 4 % of patients [1, 2]. Response to chemotherapy
is poor in the setting of _HER2_-mutant advanced NSCLC .
The 8th edition of the TNM classification has recently come into
effect. Compared to the 7th edition published in 2009 , several
important adjustments have been made to lung cancer staging with the
aim of improving prognostication and research .